Ensure patients receive the best possible care and outcomes • Help to source EQA material

New diagnosis (or relapsed) leukaemia

- Including AML (MDS), MPN, ALL and CLL cases
- Peripheral blood: WCC >50 x10^9/L
- Bone marrow: >50% blasts, WCC ~100 x10^9/L
- Sample(s) acquired preferably before treatment

Paroxysmal Nocturnal Haemoglobinuria • >10% clone

UK NEQAS
Leucocyte Immunophenotyping

NHS

Specimens in EDTA • No recent clinical history of infection with COSHH class 2, 3 or 4 HG agent

Please contact us as soon as possible if a case presents in your laboratory/ward/clinic, we can…

- Quickly clarify sample volume/parameter requirements – we can often utilise **routine *waste* patient material**
- Support sample donations for EQA/PT via informed consent
- Arrange specimen collection/transport (at no cost to your centre)
- Ensure minimal disruption to patient management/your working day

Tel: +44 (0) 114 2673600
email: scientist@ukneqasli.co.uk
www.ukneqasli.co.uk

Thank you

v2.0 (Oct 2025)QRC

Ensure patients receive the best possible care and outcomes • Help to source EQA material
New diagnosis (or relapsed) leukaemia

Including AML (MDS), MPN, ALL and CLL cases
Peripheral blood: WCC >50 x10^9/L
Bone marrow: >50% blasts, WCC ~100 x10^9/L
Sample(s) acquired preferably before treatment
Paroxysmal Nocturnal Haemoglobinuria • >10% clone
UK NEQAS
Leucocyte Immunophenotyping
NHS
Specimens in EDTA • No recent clinical history of infection with COSHH class 2, 3 or 4 HG agent
Please contact us as soon as possible if a case presents in your laboratory/ward/clinic, we can…
Quickly clarify sample volume/parameter requirements – we can often utilise routine waste patient material
Support sample donations for EQA/PT via informed consent
Arrange specimen collection/transport (at no cost to your centre)
Ensure minimal disruption to patient management/your working day
Tel: +44 (0) 114 2673600
email: scientist@ukneqasli.co.uk
www.ukneqasli.co.uk
Thank you
v2.0 (Oct 2025)QRC
Ensure patients receive the best possible care and outcomes • Help to source EQA material
New diagnosis (or relapsed) leukaemia

Including AML (MDS), MPN, ALL and CLL cases
Peripheral blood: WCC >50 x10^9/L
Bone marrow: >50% blasts, WCC ~100 x10^9/L
Sample(s) acquired preferably before treatment
Paroxysmal Nocturnal Haemoglobinuria • >10% clone
UK NEQAS
Leucocyte Immunophenotyping
NHS
Specimens in EDTA • No recent clinical history of infection with COSHH class 2, 3 or 4 HG agent
Please contact us as soon as possible if a case presents in your laboratory/ward/clinic, we can…
Quickly clarify sample volume/parameter requirements – we can often utilise routine waste patient material
Support sample donations for EQA/PT via informed consent
Arrange specimen collection/transport (at no cost to your centre)
Ensure minimal disruption to patient management/your working day
Tel: +44 (0) 114 2673600
email: scientist@ukneqasli.co.uk
www.ukneqasli.co.uk
Thank you
v2.0 (Oct 2025)QRC
Ensure patients receive the best possible care and outcomes • Help to source EQA material
New diagnosis (or relapsed) leukaemia

Including AML (MDS), MPN, ALL and CLL cases
Peripheral blood: WCC >50 x10^9/L
Bone marrow: >50% blasts, WCC ~100 x10^9/L
Sample(s) acquired preferably before treatment
Paroxysmal Nocturnal Haemoglobinuria • >10% clone
UK NEQAS
Leucocyte Immunophenotyping
NHS
Specimens in EDTA • No recent clinical history of infection with COSHH class 2, 3 or 4 HG agent
Please contact us as soon as possible if a case presents in your laboratory/ward/clinic, we can…
Quickly clarify sample volume/parameter requirements – we can often utilise routine waste patient material
Support sample donations for EQA/PT via informed consent
Arrange specimen collection/transport (at no cost to your centre)
Ensure minimal disruption to patient management/your working day
Tel: +44 (0) 114 2673600
email: scientist@ukneqasli.co.uk
www.ukneqasli.co.uk
Thank you
v2.0 (Oct 2025)QRC
Ensure patients receive the best possible care and outcomes • Help to source EQA material
New diagnosis (or relapsed) leukaemia

Including AML (MDS), MPN, ALL and CLL cases
Peripheral blood: WCC >50 x10^9/L
Bone marrow: >50% blasts, WCC ~100 x10^9/L
Sample(s) acquired preferably before treatment
Paroxysmal Nocturnal Haemoglobinuria • >10% clone
UK NEQAS
Leucocyte Immunophenotyping
NHS
Specimens in EDTA • No recent clinical history of infection with COSHH class 2, 3 or 4 HG agent
Please contact us as soon as possible if a case presents in your laboratory/ward/clinic, we can…
Quickly clarify sample volume/parameter requirements – we can often utilise routine waste patient material
Support sample donations for EQA/PT via informed consent
Arrange specimen collection/transport (at no cost to your centre)
Ensure minimal disruption to patient management/your working day
Tel: +44 (0) 114 2673600
email: scientist@ukneqasli.co.uk
www.ukneqasli.co.uk
Thank you
v2.0 (Oct 2025)QRC